BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6494827)

  • 1. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
    Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
    Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
    Kida T; Higuchi Y
    Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
    Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
    Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
    Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
    Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
    Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
    Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone scintigraphy, plasma ALP, TAP and PAP in patients with prostatic cancer].
    Imamura A; Hoshi H; Jinnouchi S; Samejima M; Watanabe K
    Kaku Igaku; 1988 Feb; 25(2):177-81. PubMed ID: 3386031
    [No Abstract]   [Full Text] [Related]  

  • 7. Bone imaging and serum phosphatases in prostatic carcinoma.
    Bishop MC; Hardy JG; Taylor MC; Wastie ML; Lemberger RJ
    Br J Urol; 1985 Jun; 57(3):317-24. PubMed ID: 4005501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW; Siddall JK; Cooper EH
    Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.
    Merrick MV; Ding CL; Chisholm GD; Elton RA
    Br J Urol; 1985 Dec; 57(6):715-20. PubMed ID: 4084732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bone scintigraphy in bone metastases due to prostatic cancer].
    Hidaka H; Ishino Y; Nakayama C; Nakata H; Okamura T
    J UOEH; 1987 Dec; 9(4):369-77. PubMed ID: 3438611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase (PAP) in blood by PAP RIA kit "EIKEN" (author's transl)].
    Kida T; Higuchi Y
    Kaku Igaku; 1981 Aug; 18(7):907-15. PubMed ID: 7321322
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.
    Gerber G; Chodak GW
    Urology; 1991 May; 37(5):418-22. PubMed ID: 2024388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer.
    Killian CS; Vargas FP; Pontes EJ; Beckley S; Slack NH; Murphy GP; Chu TM
    Prostate; 1981; 2(2):187-206. PubMed ID: 7301655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
    Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
    Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow aspiration biopsy and bone scanning in the staging of prostatic cancer.
    Varenhorst E; Alund G; Lindström E; Månson JC
    Br J Urol; 1983 Oct; 55(5):534-7. PubMed ID: 6626900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of two serum isoenzyme phosphatases as bone metastasis markers].
    Desoize B; Pourny C; Amico S; Larbre H; Jardillier JC
    Bull Cancer; 1990; 77(12):1211-21. PubMed ID: 2081281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone scanning and plasma phosphatases in carcinoma of the prostate.
    O'Donoghue EP; Constable AR; Sherwood T; Stevenson JJ; Chisholm GD
    Br J Urol; 1978 May; 50(3):172-7. PubMed ID: 753455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.